GERN — Geron Corporation
$1.150.00%
Last close: · regular session
Last 60 sessions
GERN closed at $1.15 (0.00%) on Oct 27, 2026. Active automatic shelf (S-3ASR, Mar 2026); dilution risk: low. Float: 626.7M shares. Latest SEC filing: SCHEDULE 13G on Aug 7, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GERN in the TickerWise workspace.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 229
- Website: https://www.geron.com
Latest SEC filings for GERN
Latest GERN news
- Geron drops after discontinuing late-stage trial for Rytelo Read article
- Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 Read article
- Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? Read article
- Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN Read article
- Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.